Market Overview - The Hong Kong stock market experienced a rise followed by a slight retreat, with the Hang Seng Index closing at 27,183.15 points, up 0.58% or 155.99 points, and a total trading volume of HKD 234.04 billion [1] - The Hang Seng China Enterprises Index increased by 0.81% to 9,242.75 points, while the Hang Seng Tech Index rose by 0.62% to 5,451.03 points [1] Blue-Chip Stocks Performance - Pop Mart (09992) continued its upward trend, closing up 4.9% at HKD 269.8, contributing 14.96 points to the Hang Seng Index [2] - Other notable blue-chip stocks included: - CSPC Pharmaceutical Group (01093) up 5.52% at HKD 10.32, contributing 7.01 points [2] - Innovent Biologics (01801) up 4.98% at HKD 89.65, contributing 11.16 points [2] - New Oriental Education (09901) down 4.39% at HKD 46.66, detracting 2.61 points [2] - Alibaba Health (00241) down 2.07% at HKD 6.14, detracting 1.34 points [2] Sector Highlights - The biotechnology sector showed strong performance, with notable gains from: - CSPC Pharmaceutical Group (01093) up 5.52% [3] - Genscript Biotech (01672) up 5.15% [3] - Innovent Biologics (01801) up 4.98% [3] - WuXi Biologics (02269) up 4.65% [3] - The AI-related stocks also surged, with: - China Literature (00772) up 15.41% [4] - Zhiyun (02513) up 14.81% [4] - Fubo Group (03738) up 14.44% [4] Investment Opportunities - The global strategic cooperation between Innovent Biologics and Eli Lilly could reach a potential transaction value of USD 8.85 billion, indicating a strong start for 2026 in business development [4] - The North American electricity shortage is expected to drive investments in various technologies, with the Department of Energy predicting a peak shortfall of 20-40 GW by 2030 [6] Notable Stock Movements - Lexin Outdoor (02720) saw a significant increase of 102.29% on its first trading day, closing at HKD 24.78 [7] - Ruifeng New Energy (00527) rose by 12.9% after signing an investment framework agreement for a major AI computing center project in Zhangjiakou, with a total investment of approximately RMB 24 billion [8] - Jizhi Technology (02590) increased by 11.05% after launching a new general-purpose robot for warehouse scenarios [9] - Ninepoint Investment Holdings (09636) issued a profit warning, expecting revenue of approximately RMB 3.43 billion for 2025, a growth of about RMB 1.12 billion [10] - Changfei Optical Fiber (06869) reached a new high, closing up 8.88% as fiber prices have been rising due to supply-demand imbalances [11]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while the median is 32.64x, with pharmaceutical distribution having the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market is on GLP-1 targets, with Eli Lilly's Tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches, and key supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and achieve cross-border collaboration milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Group 1 - The core viewpoint of the articles indicates that AstraZeneca expects a double-digit percentage growth in adjusted earnings per share by 2026, driven by strong sales in its oncology drug business, which will offset the impact of patent expirations on core diabetes drugs [1] - AstraZeneca's fourth-quarter profits and revenues met expectations, with the company forecasting mid-to-high single-digit revenue growth for the year, similar to the 8% increase in 2025, allowing room for potential upward revisions later in the year [1][2] - The company is accelerating its entry into the weight loss drug market, having recently signed a collaboration agreement with China’s CSPC Pharmaceutical Group worth up to $18.5 billion, which includes access to CSPC's long-acting peptide technology platform for developing next-generation weight loss therapies [1] Group 2 - AstraZeneca's self-developed oral GLP-1 drug, elecoglipron, has entered late-stage clinical trials, becoming a key candidate in its obesity treatment pipeline [1] - The company has confidence in managing pricing impacts and is focused on achieving its long-term revenue target of $80 billion by 2030, with several new drugs in clinical development being critical for maintaining growth momentum [2] - Under CEO Pascal Soriot's leadership, AstraZeneca has established a leading position in oncology and is the second-largest listed company on the London Stock Exchange, with key clinical data for new drugs targeting diseases like lung cancer and COPD expected to be released this year [3]

Group 1 - The Hong Kong stock market closed with the Hang Seng Index rising by 0.58% and the Tech Index increasing by 0.62% [1] - Le Xin Outdoor (02720.HK) saw a first-day listing surge of over 100% [1] - CSPC Pharmaceutical Group (01093.HK) experienced a rise of over 5.5% [1] - Innovent Biologics (01801.HK) and Pop Mart (09992.HK) both increased by nearly 5% [1] - Oriental Selection (01797.HK) faced a decline of nearly 10% [1]

Market Overview - The Hong Kong stock market exhibited a "structural differentiation" trend on February 10, with a strong wait-and-see sentiment before the holiday. The Hang Seng Index rose by 0.58% to 27,183.15 points, the Hang Seng Tech Index increased by 0.62% to 5,451.03 points, the National Enterprises Index climbed by 0.81% to 9,242.75 points, and the Red Chip Index gained 0.27% to 4,407.29 points [1] Individual Stock Highlights - Evergrande Property saw a significant increase of 5.36% to 1.18 HKD, driven by news of potential bidders submitting updated offers for the company's assets, indicating progress in the liquidation process [2] - The stock of Geekplus Technology surged by 11.37% to 28.02 HKD following the launch of its Gino 1 warehouse robot, which is expected to accelerate the adoption of unmanned warehouses [3] - Yiteng Jiahe rose nearly 7% due to the completion of the first dosing in Phase II clinical trials for its ANGPTL3 siRNA drug EDP167 [4] - Bubble Mart received a favorable outlook from Macquarie, with a reiterated "outperform" rating, projecting global sales to exceed 400 million units by 2025 [5] Sector Performance - The AI and robotics sector emerged as a strong focus, with multiple stocks experiencing significant gains, including MiniMax-WP and Zhiyuan, which saw increases of 24% and 11%, respectively [3] - Pharmaceutical and technology hardware stocks also showed positive performance, with notable gains from companies like Singularity and Gree Medical, benefiting from favorable policy changes and strategic investments [4] Institutional Insights - Dongwu Securities noted that despite increased inflows from southbound funds, overall trading volume in the Hong Kong market has decreased, influenced by global tech stock capital expenditure concerns [6] - Analysts from Jianyin International indicated that the valuation recovery of Hong Kong stocks is nearly complete, shifting the investment logic from "valuation recovery" to "new productive forces" [6] - Analysts emphasized that the continuous inflow of southbound funds could enhance market sentiment and strengthen the pricing power of mainland funds in the Hong Kong market [6]

恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，精准汇聚港股创新药领军 企业；中证港股通医药卫生综合指数从港股通范围内选取医药卫生行业中市值较大的50只上市公司作为 样本，覆盖创新药、医疗器械等领域。投资者可通过港股通创新药ETF易方达（159316）、港股通医药 ETF易方达（513200）等跟踪上述指数的产品，精准捕捉医药产业发展机遇。 1月30日，石药集团与阿斯利康达成总额高达185亿美元的合作，首付款12亿美元，创下中国药企对外授 权交易新纪录。2月8日，信达生物与礼来达成88.5亿美元合作，首付3.5亿美元，创新采用"端到端共 研"模式。据统计，2026年以来创新药BD合作的首付款规模，已超越2025年全年最高单季度水平，总交 易金额已达332.8亿美元，产业出海势头迅猛。 同时，龙头公司业绩预告验证了高景气度。信达生物、荣昌生物与君实生物预告2025年营业收入分别约 为110亿元、32.5亿元和25亿元，同比大幅增长45%、89%和32%，强劲的业绩增长为板块提供了坚实的 基本面支撑。 2月10日，港股医药板块全天强势领涨，截至15:15，恒生港股通创新药指数上涨2.7 ...

港股通创新药ETF跟踪中证港股通创新药指数，指数编制方式更科学合理，成分股涵盖如百济神州、信达生物和药明生物等龙头企业。 港股通创新药ETF易方达是目前市场上唯一跟踪恒生港股通创新药指数的产品，该指数在编制方案中明确剔除了CXO公司，聚焦创新药产业核心企业，权重 股包括百济神州、信达生物、药明生物、康方生物等龙头公司，为投资者布局港股前沿创新药企提供了便捷工具。 港股创新药上涨，石药集团、药明生物、信达生物涨超5%，带动港股通创新药ETF嘉实、港股通创新药ETF万家、港股创新药50ETF、港股通创新药ETF鹏 华、港股创新药ETF、恒生生物科技ETF南方、港股通创新药ETF、港股创新药ETF、港股通创新药ETF南方、港股通创新药ETF工银、港股通创新药ETF、 恒生生物科技ETF易方达、 港股通医疗ETF富国上涨。 | 证券代码 | 证券简称 | 当日涨幅% | 年内涨幅 | 管理 | | --- | --- | --- | --- | --- | | 520970.SH | 港股通创新药ETF嘉实 | 3.27% | 11.03% | 嘉委 | | 520700.SH | 港股通创新药ETF万家 | 3.1 ...

从基本面看，创新药业绩预告验证产业景气。信达生物、荣昌生物和君实生物预告2025年收入约 110/32.5/25亿元，分别同比增长45%/89%/31.8% 国金证券认为，2-3月有望迎来创新药企业的业绩披露窗口，多家药企有望迎来减亏或扭亏，同时预计 2026年更多创新药企业有望扭亏并大幅释放利润；展望全年，AACR（4月）、ASCO（5月）、ESMO （10月）等学术会议上国产创新药有望进一步带来临床数据的兑现；整体上，创新药前期回调较为充 分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。 港股创新药上涨，截至发稿，港股通创新药ETF易方达(159316)涨2.89%，港股通医药ETF易方达 (513200)涨2.33%。 板块反弹主要受BD交易密集落地、预告业绩高增及流动性改善三重利好驱动。 创新药重磅BD频出：石药集团×阿斯利康：1月30日达成185亿美元合作（首付12亿美元），创中国药企 BD纪录； 信达生物×礼来：2月8日达成88.5亿美元合作（首付3.5亿美元），采用"端到端共研"模式； 2026年以来创新药BD首付款规模已超25年全年最高单季度水平，总交易金额达332.8亿美元（占25 ...

Group 1 - The core viewpoint of the news highlights significant advancements in the biotech sector, particularly in the collaboration between Innovent Biologics and Eli Lilly, which focuses on new drug development in oncology and immunology, with a deal size exceeding expectations [1] - The collaboration employs a "China PoC + global development" model, leveraging Innovent's efficient clinical validation capabilities in China while utilizing Eli Lilly's global commercialization network to mitigate risks, marking a key step in the globalization of Chinese innovative pharmaceutical companies [1] - The assets involved in the collaboration, such as IBI363 and IBI343, have entered global multi-center Phase III clinical trials, with a combined potential market space of $60 billion [1] Group 2 - The ADC commercialization process is accelerating, with 20 ADC drugs approved globally, six of which have consistently been in the "billion-dollar club" for two years; approximately 60 are in Phase III clinical trials or awaiting market approval [2] - Local companies are increasingly gaining advantages due to their self-commercialization capabilities, as seen with Rongchang Biologics transitioning from outsourcing to in-house production, and Keren Biotechnology and Baillie Tianheng accelerating the establishment of their own production bases [2] - The Hong Kong Innovation Drug ETF has seen a strong performance, with a 3.10% increase as of February 10, 2026, and a total scale of 25.98 billion yuan, indicating a positive trend in investment within the sector [2]

Market Overview - The A-share market is experiencing narrow fluctuations, with a focus on AI applications, while traditional sectors like liquor and non-ferrous metals are facing declines, impacting major indices [1] - As of the midday break, the Shanghai Composite Index is at 4122.34 points, down 0.02%, the Shenzhen Component Index is down 0.02%, and the ChiNext Index is down 0.14%, while the Sci-Tech Innovation Board Index is up 0.19% [1] AI Application Sector - The AI application sector has seen significant activity, particularly in the "AI + Film" direction, leading to a surge in stock prices, with over ten film-related stocks hitting the daily limit [2] - Notable stocks include: - Jiecheng Co., Ltd. (300182) and Zhongwen Online (300364) both achieving a 20% increase for two consecutive days - Industry leader Light Media (300251) also rising by 20% [2][3] Seedance 2.0 Impact - The recent internal testing of ByteDance's Seedance 2.0 video model has sparked widespread discussion, showcasing its ability to create high-quality videos from text or images in just 60 seconds [4] - Analysts believe that Seedance 2.0 represents a breakthrough in AI capabilities, potentially revolutionizing the production of short content like AI dramas and significantly reducing costs and increasing efficiency in production [4] Innovative Drug Sector - The innovative drug sector is experiencing a revival after a period of stagnation, with Wanbangde (002082) hitting the daily limit and Guangshengtang (300436) rising over 8% [6] - The National Medical Products Administration has announced that by 2025, China's pharmaceutical industry will accelerate its internationalization, with innovative drug overseas licensing transactions expected to exceed $130 billion, marking a shift from a "generic drug production powerhouse" to an "innovative drug exporting powerhouse" [8]